Skip to contentM
Marker Therapeutics, Inc.
M
MRKRMarker Therapeutics, Inc. Q3 2025 · 10-Q
Revenue$1.23M$1.23M−36.0% vs Q3 2024 Net Income-$2.00M-$2.00MN/M vs Q3 2024 EPS Diluted-$0.12-$0.12N/M vs Q3 2024 Operating Income-$2,136,726N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Marker Therapeutics, Inc. · CIK 1094038 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-173.3%−48.7 pt vs Q3 2024
Net margin-162.1%−42.3 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 13, 2025 · 44 d after period end